Watchlist Price Alert

Agios Pharmaceuticals Inc... (AGIO)

NASDAQ: AGIO · Real-Time Price · USD

35.50

1.20 (3.50%)

At close: Jun 16, 2025, 3:59 PM

35.06

-1.24%

After-hours: Jun 16, 2025, 04:17 PM EDT

3.50% (1D)

Bid	31
Market Cap	2.06B
Revenue (ttm)	37.03M
Net Income (ttm)	665.99M
EPS (ttm)	11.54
PE Ratio (ttm)	3.08
Forward PE	-5.19
Analyst	Buy

Ask	36.8
Volume	509,198
Avg. Volume (20D)	615,250
Open	34.50
Previous Close	34.30
Day's Range	33.77 - 36.32
52-Week Range	23.42 - 62.58
Beta	0.73

About AGIO

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol AGIO

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for AGIO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

7 months ago

-4.04%

Agios Pharmaceuticals shares are trading lower aft... Unlock content with Pro Subscription

8 months ago

-5.08%

Agios Pharmaceuticals shares are trading lower after Leerink Partners downgraded the stock from Outperform to Market Perform and cut its price target on the stock from $60 to $56.

News

1 week ago · businesswire.com

Avanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND® in Rare Blood Disorders

AMSTERDAM--(BUSINESS WIRE)-- #biotech--Avanzanite Bioscience B.V. (“Avanzanite”), a fast-growing commercial-stage specialty pharmaceutical company dedicated to bringing rare disease medicines to patie...

1 month ago · zacks.com

Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates

AGIO's earnings beat estimates in the first quarter of 2025, while revenues miss the same.

1 month ago · seekingalpha.com

Agios Pharmaceuticals, Inc. (AGIO) Q1 2025 Earnings Call Transcript

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants Chris Taylor – Vice President-Investor Relations and Corporate Communications Br...

1 month ago · zacks.com

Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Misses Revenue Estimates

Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.55 per share versus the Zacks Consensus Estimate of a loss of $1.80. This compares to loss of $1.45 per share a year ago.

1 month ago · zacks.com

Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for

Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.